Follow
Andrew Blauvelt
Andrew Blauvelt
Investigator, Oregon Medical Research Center
Verified email at oregonmedicalresearch.com
Title
Cited by
Cited by
Year
Two phase 3 trials of dupilumab versus placebo in atopic dermatitis
EL Simpson, T Bieber, E Guttman-Yassky, LA Beck, A Blauvelt, MJ Cork, ...
New England Journal of Medicine 375 (24), 2335-2348, 2016
17142016
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded …
A Blauvelt, M de Bruin-Weller, M Gooderham, JC Cather, J Weisman, ...
The Lancet 389 (10086), 2287-2303, 2017
11502017
Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis
KB Gordon, A Blauvelt, KA Papp, RG Langley, T Luger, M Ohtsuki, ...
New England Journal of Medicine 375 (4), 345-356, 2016
9052016
Human skin Langerhans cells are targets of dengue virus infection
SJL Wu, G Grouard-Vogel, W Sun, JR Mascola, E Brachtel, R Putvatana, ...
Nature medicine 6 (7), 816-820, 2000
9022000
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe …
A Blauvelt, KA Papp, CEM Griffiths, B Randazzo, Y Wasfi, YK Shen, S Li, ...
Journal of the american academy of dermatology 76 (3), 405-417, 2017
8602017
Circulating Th17, Th22, and Th1 cells are increased in psoriasis
S Kagami, HL Rizzo, JJ Lee, Y Koguchi, A Blauvelt
Journal of Investigative Dermatology 130 (5), 1373-1383, 2010
8232010
IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice
JS Cho, EM Pietras, NC Garcia, RI Ramos, DM Farzam, HR Monroe, ...
The Journal of clinical investigation 120 (5), 1762-1773, 2010
7122010
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
D Thaçi, A Blauvelt, K Reich, TF Tsai, F Vanaclocha, K Kingo, M Ziv, ...
Journal of the American Academy of Dermatology 73 (3), 400-409, 2015
6382015
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose …
D Thaci, EL Simpson, LA Beck, T Bieber, A Blauvelt, K Papp, W Soong, ...
The Lancet 387 (10013), 40-52, 2016
6152016
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and …
KB Gordon, B Strober, M Lebwohl, M Augustin, A Blauvelt, Y Poulin, ...
The Lancet 392 (10148), 650-661, 2018
5932018
Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis
EG Harper, C Guo, H Rizzo, JV Lillis, SE Kurtz, I Skorcheva, D Purdy, ...
Journal of Investigative Dermatology 129 (9), 2175-2183, 2009
5672009
The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis
A Blauvelt, A Chiricozzi
Clinical reviews in allergy & immunology 55 (3), 379-390, 2018
5662018
Expression and function of CCR5 and CXCR4 on human Langerhans cells and macrophages: implications for HIV primary infection
M Zaitseva, A Blauvelt, S Lee, CK Lapham, V Kiaus-Kovrun, H Mostowski, ...
Nature medicine 3 (12), 1369-1375, 1997
5281997
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
K Reich, KA Papp, A Blauvelt, SK Tyring, R Sinclair, D Thaçi, K Nograles, ...
The Lancet 390 (10091), 276-288, 2017
5262017
Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis
KA Papp, A Blauvelt, M Bukhalo, M Gooderham, JG Krueger, JP Lacour, ...
New England Journal of Medicine 376 (16), 1551-1560, 2017
5152017
Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5
MM Lederman, RS Veazey, R Offord, DE Mosier, J Dufour, M Mefford, ...
Science 306 (5695), 485-487, 2004
4832004
Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines
E Fitch, E Harper, I Skorcheva, SE Kurtz, A Blauvelt
Current rheumatology reports 9 (6), 461-467, 2007
4822007
A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis
KA Papp, K Reich, C Paul, A Blauvelt, W Baran, C Bolduc, D Toth, ...
British Journal of Dermatology 175 (2), 273-286, 2016
4672016
Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)
A Wollenberg, A Blauvelt, E Guttman‐Yassky, M Worm, C Lynde, ...
British Journal of Dermatology 184 (3), 437-449, 2021
3992021
Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial
EL Simpson, AS Paller, EC Siegfried, M Boguniewicz, L Sher, ...
JAMA dermatology 156 (1), 44-56, 2020
3932020
The system can't perform the operation now. Try again later.
Articles 1–20